Picture1.png
CBIH Unveils the Future of Wellness with Revolutionary Anti-Aging Chip
November 25, 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
our Research and Development team is redefining the possibilities of cannabinoid-based biotechnologies and at the heart of these innovations lies the Rejuv
800 px horizontal logo.png
CORRECTION - Elevai Labs Inc.
November 14, 2024 14:35 ET | Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
22157.jpg
Bone Metabolism Assays Pipeline Research Report 2024 Stages of Development, Region and Countries, Regulatory Path Key Companies, Licensing and Collaboration Details
November 14, 2024 09:11 ET | Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Bone Metabolism Assays Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update"...
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
October 22, 2024 09:54 ET | Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
October 21, 2024 07:30 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl
800 px horizontal logo.png
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
October 03, 2024 15:45 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
October 03, 2024 07:30 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
BioNTX StandardMed_Res.jpg
BioNTX Announces the 2024 Dennis K. Stone Award Recipient
October 01, 2024 10:48 ET | BioNTX
DALLAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioNTX, the bioscience and healthcare innovation trade organization serving North Texas, is pleased to introduce D. Jeff Keyser, RPh, JD, PhD as the...
BioNTX StandardMed_Res.jpg
BioNTX Announces 2024 Tech Transfer Showcase Finalists Pitch Competition at the 2024 iC³ Life Science & Healthcare Innovation Summit
September 26, 2024 10:00 ET | BioNTX
ARLINGTON, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- BioNTX is pleased to announce the finalists for the 3rd Annual Tech Transfer Showcase, set for Friday, October 4th, at the 2024 iC³ Life Science...
Lifeist.png
Lifeist Reports Executive Management Update
September 26, 2024 07:00 ET | Lifeist Wellness Inc.
Lifeist provides executive update